OBI Pharma Announces First Cancer Patient Enrolled on OBI-999 in Phase 2 Study

OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that the first patient has been enrolled on the Phase 2 study of OBI-999. OBI-999 is a novel antibody drug conjugate (ADC) cancer therapy targeting cancer with overexpression of Globo H. By releasing a small molecule chemotherapeutic drug through the specificity of the antibody, it […]

This article is password protected.

To view the content, please enter your password in the field below